

Article

Whole-Genome Sequence Analysis of Colistin-Resistant, *mcr*-Harboring *Escherichia coli* Isolated from a Swine Slaughterhouse in Thailand

Ratchadaporn Boripun ^{1,2,*}, Pakpoom Tadee ³, Ravisa Warin ^{1,2}, Naparat Suttidate ^{1,2}, Doan Hoang Phu ⁴, Hidenori Kabeya ⁵, Chaithep Poolkhet ^{1,2}, Sumalee Boonmar ^{1,2}, Suchawadee Tesakul ¹, Yanika Klainiem ¹ and Nuttapong Pavana ¹

¹ Akkhraratchakumari Veterinary College, Walailak University, Nakhon Si Thammarat 80160, Thailand; ravisa.wa@wu.ac.th (R.W.); naparat.st@mail.wu.ac.th (N.S.); chaithep.po@wu.ac.th (C.P.); sumaleeka12@gmail.com (S.B.); suchawadee.1805@gmail.com (S.T.); pair.yanika@gmail.com (Y.K.); midfild2014@gmail.com (N.P.)

² One Health Research Center, Walailak University, Nakhon Si Thammarat 80160, Thailand

³ Department of Food Animal Clinics, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand; td.pakpoom@gmail.com

⁴ Department of Agriculture, Gia Lai Campus, Nong Lam University HCMC, Ho Chi Minh City 720000, Vietnam; dhoangphu@hcmuaf.edu.vn

⁵ Laboratory of Veterinary Food Hygiene, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, 1866 Kameino, Fujisawa 252-0880, Kanagawa, Japan; kabeya.hidenori@nihon-u.ac.jp

* Correspondence: kikkyrb@gmail.com or ratchadaporn.bo@wu.ac.th

Abstract

The emergence of colistin-resistant *Escherichia coli* (*E. coli*) in livestock poses a major public health concern due to its zoonotic potential and multidrug resistance (MDR). The study aimed to detect mobilized colistin resistance genes (*mcr-1* to *mcr-9*) in *E. coli* isolates, along with characterizing their antimicrobial susceptibility, resistance genes, virulence genes, and whole genome sequencing. We investigated *E. coli* contamination in a swine slaughterhouse in Nakhon Si Thammarat Province, Thailand. A total of 200 fecal samples were collected and screened for *E. coli* using selective media supplemented with colistin. A total of 200 fecal samples were collected from a swine slaughterhouse and screened for *E. coli* using selective media supplemented with colistin. Presumptive *E. coli* isolates were confirmed by PCR, followed by molecular detection of *mcr-1* to *mcr-9* genes. Antimicrobial susceptibility testing was performed using the disk diffusion method. Selected isolates were further analyzed for additional antimicrobial resistance genes and virulence associated genes by PCR. Whole genome sequencing was conducted on representative isolates exhibiting high levels of antimicrobial resistance. Our results showed that out of 200 fecal samples, 124 presumptive *E. coli* isolates were recovered from a swine slaughterhouse using selective media containing colistin. PCR confirmation identified 112 isolates (90.32%) as *E. coli*. Molecular detection of mobilized colistin resistance (*mcr*) genes (82 isolates, 73.21%) demonstrated that *mcr-1* (50.89%) was the most prevalent, followed by *mcr-9* (25.89%) and *mcr-3* (24.11%). Overall, the 82 *mcr E. coli* isolates showed the highest level of resistance to ampicillin (97.56%), followed by tetracycline (95.12%), piperacillin (73.17%), and chloramphenicol (65.85%). For non-*mcr E. coli* isolates, the highest resistance percentage was observed for ampicillin (96.67%), followed by piperacillin (80%) and tetracycline (73.33%). Among the isolates, 75% exhibited MDR phenotypes, showing 22 distinct resistance profiles. The most common MDR pattern was AMP-PIP-TE-C-S (12.5%). Additional antimicrobial resistance genes, including *aadA*, *ampC*, and *bla*_{TEM}, were detected in over 60% of a subset of 30 tested isolates. The virulence gene analysis revealed that *eae* (74.10%), associated



Academic Editor: Nahla O. Eltai

Received: 26 December 2025

Revised: 23 January 2026

Accepted: 26 January 2026

Published: 29 January 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

with enteropathogenic *E. coli* (EPEC), was the predominant pathotype. Whole genome sequencing of five selected isolates confirmed the presence of multiple antimicrobial resistance and virulence determinants. In conclusion, this study reveals a high prevalence of MDR *E. coli* harboring colistin resistance genes (*mcr-1* to *mcr-9*) in a swine slaughterhouse in southern Thailand. The findings highlight the potential risk of zoonotic transmission of antimicrobial resistant *E. coli* through the food production chain and emphasize the importance of continuous genomic surveillance and prudent antimicrobial use in livestock production systems.

Keywords: colistin; multidrug resistance; *Escherichia coli*; swine; *mcr*-encode gene; whole genome sequencing

1. Introduction

Escherichia coli is recognized as a major foodborne infection, affecting millions of individuals annually [1,2]. The food involved in primary transmission is livestock products, including raw beef, pork, and chicken meat [3–5]. Existing research highlights that microbial contamination predominantly occurs throughout the production chain, from farm to fork, with a significant prevalence during the slaughtering processes [6,7]. Several pathogenic *E. coli* have been identified, based on bacterial genetics and associated pathologies, including Enteropathogenic *E. coli* (EPEC), Shiga toxin-producing *E. coli* (STEC), Enterohemorrhagic *E. coli* (EHEC), Enterotoxigenic *E. coli* (ETEC), Enteroinvasive *E. coli* (EIEC), Enteraggregative *E. coli* (EAEC), Diffuse adhering *E. coli* (DAEC), and Adherent-invasive *E. coli* (AIEC). The pathogens cause various intestinal diseases, such as watery or bloody diarrhea, hemolytic uremic syndrome (HUS), and colitis [8]. In swine production, colistin, an antimicrobial medicine, has been excessively used in the treatment of *E. coli* infection or colibacillosis, as well as a growth promoter, contributing to the emergence of antimicrobial resistance (AMR) [9,10] and the spread of zoonotic colistin-resistant strains [11].

Swine farms have been reported as major reservoirs for mobile colistin resistance (*mcr*) genes, as *mcr*-positive *E. coli* have been identified from swine farms in Central China [12]. Moreover, colistin-resistant *E. coli* has isolated from swine and pork across Southeast Asian countries, including Thailand, the Lao PDR, and Cambodia [4,11]. This highlights the emerging concern of this issue since the detection of colistin-resistant *E. coli* in swine and pork reflects the intensive use of colistin in swine production [13]. The occurrence of *mcr*-encoded colistin resistance in *E. coli* has not only been documented in swine but also in farm workers, suggesting potential zoonotic transmission between animals and humans [14]. The persistence of colistin-resistant bacteria harboring plasmid-mediated *mcr* genes is concerning, as they may cause serious nosocomial infections in human hospitals [10,15]. Moreover, colistin, a priority antimicrobial (HPCIA) drug, should be reserved as a last-resort treatment for severe infections caused by Gram-negative multidrug-resistant (MDR) bacteria in humans [16]. This means that bacterial infections have become more difficult to treat effectively.

Transportation immediately prior to slaughter is a major stressor in livestock and can trigger neuroendocrine activation, including increased cortisol release, which may impair immune competence and compromise gastrointestinal barrier function [17,18]. These stress-related physiological changes can disrupt the gut microbial ecosystem, leading to microbial imbalance and facilitating the expansion of enteric pathogens [19]. Such alterations have been linked to elevated intestinal pathogen burdens and increased fecal shedding, notably *Salmonella*, thereby raising the risk of environmental dissemination and carcass contamina-

tion [7,18,20]. In parallel, antimicrobial resistance (AMR) poses a growing public health and economic burden in Thailand, including increased hospitalization, treatment costs, and mortality, underscoring the importance of AMR surveillance and integrated prevention and control strategies under the One Health concept [21–23]. Given the global rise in AMR-associated morbidity and mortality [24,25], this study aimed to characterize antimicrobial resistance phenotypes and determine the prevalence of mobile colistin resistance (*mcr*) among *E. coli* isolates recovered from swine feces at a swine slaughterhouse in Southern Thailand. We further screened for resistance genes relevant to antimicrobials commonly monitored in pork production chains, including phenicols, aminoglycosides, β -lactams, and tetracyclines [26], and performed whole-genome sequencing of five selected isolates for in-depth molecular characterization.

2. Results

2.1. Prevalence of *Mcr* *Escherichia coli* from a Swine Slaughterhouse

In a total of 200 feces samples, 124 isolates were selected, based on lactose fermentation on MacConkey agar containing 4 mg/L of colistin and the presence of colonies with a metallic sheen color on EMB agar, which were predicted to be colistin-resistant *E. coli*. Among the isolates, 112 (90.32%) were confirmed as *E. coli* by the detection of the *uidA* gene using PCR analysis. For colistin resistance genes *mcr-1* to 9, there were 82 isolates of *mcr* *E. coli* from the 112 isolates (73.21%). The prevalence of each *mcr* gene (*mcr-1* to *mcr-9*) is shown in Table 1. The prevalence of *mcr-1* *E. coli* was 50.89% (57/112), followed by 25.89% (29/112) of *mcr-9*, and 24.10% (27/112) of *mcr-3*, respectively. The prevalences of *mcr-8* *E. coli*, *mcr-4* *E. coli*, and *mcr-7* *E. coli* were 1.78% (2/112), 0.89% (1/112), and 0.89% (1/112), respectively. There were no *mcr-2* *E. coli* or *mcr-5* *E. coli*. Among the 82 *mcr*-positive isolates, the most common combination detected was *mcr-1* and *mcr-3* (12.50%), followed by *mcr-1* and *mcr-9* (8.93%). We found less frequency of *E. coli* *mcr* genes, such as *mcr-3* with *mcr-7*, *mcr-8*, or *mcr-9* (0.89–3.57%), as well as the rare coexistences of three genes: *mcr-1*, *mcr-3*, and *mcr-9* (2.68%); and *mcr-3*, *mcr-7*, and *mcr-8* (0.89%) (Table 1).

Table 1. Prevalence of *mcr* *E. coli* isolated from a swine slaughterhouse (N = 112).

<i>mcr</i> Gene	No. of <i>E. coli</i> Isolates
<i>mcr-1</i>	57 (50.89%)
<i>mcr-2</i>	0 (0%)
<i>mcr-3</i>	27 (24.11%)
<i>mcr-4</i>	1 (0.89%)
<i>mcr-5</i>	0 (0%)
<i>mcr-7</i>	1 (0.89%)
<i>mcr-8</i>	2 (1.79%)
<i>mcr-9</i>	29 (25.89%)
<i>mcr-1</i> and <i>mcr-3</i>	14 (12.50%)
<i>mcr-1</i> and <i>mcr-9</i>	10 (8.93%)
<i>mcr-3</i> and <i>mcr-7</i>	1 (0.89%)
<i>mcr-3</i> and <i>mcr-8</i>	1 (0.89%)
<i>mcr-3</i> and <i>mcr-9</i>	4 (3.57%)
<i>mcr-7</i> and <i>mcr-8</i>	1 (0.89%)
<i>mcr-1</i> , <i>mcr-3</i> , and <i>mcr-9</i>	3 (2.68%)
<i>mcr-3</i> , <i>mcr-7</i> , and <i>mcr-8</i>	1 (0.89%)

2.2. Antibiotic Susceptibility of *E. coli*

The antimicrobial susceptibility of the 112 *E. coli* isolates was tested against ten antimicrobial drugs. The percentages of antimicrobial resistance in the *mcr E. coli* isolates ($n = 82$) and non-*mcr E. coli* isolates ($n = 30$) are demonstrated in Figure 1A and 1B, respectively. Both the *mcr E. coli* and non-*mcr E. coli* groups showed no resistance (0%) to amoxicillin-clavulanic (AMC) acid. For the *mcr E. coli* group, 97.56 percent of the isolates showed a resistance to ampicillin (AMP), followed by tetracycline (TE, 95.12%), piperacillin (PIP, 73.17%), chloramphenicol (C, 65.85%), streptomycin (S, 40.24%), gentamicin (GEN, 26.83%), enrofloxacin (ENR, 10.98%), ceftriaxone (CRO, 3.66%), and amikacin (AMK, 2.44%) (Figure 1A).




Figure 1. The antimicrobial-resistance percentages of *mcr E. coli* ($n = 82$) (A) and non-*mcr E. coli* strains ($n = 30$) (B). Antimicrobial susceptibility was performed by disk diffusion assay and analyzed based on the resistance breakpoints according to CLSI (VET01S, M100) guidelines.

For non-*mcr E. coli* isolates, the highest resistance percentage was observed for AMP (96.67%), followed by PIP (80.00%), TE (73.33%), S (56.67%), C (56.67%), GEN (33.33%), ENR (10%), and there was no resistance (0%) to CRO and AMK (Figure 1B). Overall, *mcr-1*-positive isolates exhibited the broadest resistance spectrum, showing high resistance rates to AMP (68%), PIP (50%), TE (70%), C (51%), and S (28%). Moderate resistances to CRO (4%) and ENR (9%) were also observed. In contrast, *mcr-3* and *mcr-9* isolates demonstrated intermediate resistance profiles, particularly to AMP (32–35%), PIP (22–28%), TE (29–34%), and C (20–23%). Other *mcr* variants (*mcr-2*, *mcr-4*, *mcr-5*, *mcr-7*, and *mcr-8*) showed minimal or no resistance to the tested antibiotics. These findings indicated that *mcr-1* is predominantly associated with multidrug resistance, whereas other *mcr* types tended to confer narrower resistance patterns (Figure 2). Fisher's Exact test indicated a significant association between the antimicrobial resistance percentages and the percentages of positive *mcr* gene variants ($p = 0.002$).




Figure 2. Annotation heatmap of the antimicrobial resistance percentage in each *mcr E. coli* (*mcr-1* to *mcr-9*) ($n = 30$). Each cell shows the percentage of *mcr E. coli* isolates that are resistant to the listed agent. Abbreviations: AMC—amoxicillin/clavulanic acid; AK—amikacin; AMP—ampicillin; CRO—ceftriaxone; ENR—enrofloxacin; PIP—piperacillin; S—streptomycin; TE—tetracycline; C—chloramphenicol; CN—gentamicin. Color intensity increases with higher prevalence; blank cells denote 0%. Fisher’s Exact Test for frequency data with simulated p -value (based on 2000 replicates); $p = 0.002$.

2.3. MDR Patterns

The AMR patterns in *mcr*-positive *E. coli* and non-*mcr*-positive *E. coli* were presented in Table 2. The results showed that 60 of the *mcr* isolates (53.57%) and 24 of the non-*mcr* isolates (21.42%) were resistant to at least three different antimicrobial classes, indicating multidrug resistance (MDR). The most prevalent AMR pattern (12.5%) was AMP-PIP-TE-C-S, which was found in both *mcr*-positive isolates (8.92%) and non-*mcr E. coli* (3.57%). The second-most prevalent AMR pattern was AMP-PIP-TE-C (10.71%), a vast majority of which (9.82%) was found in *mcr*-positive *E. coli*. Similarly, a large majority of the third-most prevalent AMR pattern, which was AMP-TE-C, was found in *mcr*-positive *E. coli* (8.03%). Interestingly, there were seven *mcr*-positive *E. coli* isolates (6.25%) that showed resistant to five antimicrobial drug classes, while there was no isolate from non-*mcr E. coli* in this category. Moreover, the AMR patterns that were only found in the *mcr*-positive *E. coli* group were AMP-TE-C-CN, AMP-ENR-PIP-TE, AMP-ENR-TE-C, AMP-PIP-C-S, and AMP-TE-CN, which accounted for 3.57%, 0.89%, 0.89%, 0.89%, and 0.89% prevalence, respectively.

Table 2. Antimicrobial resistance patterns of *E. coli* isolates ($n = 112$) based on disk diffusion results.

Pattern	Profile	No. of Drug Classes	No. <i>mcr</i> Isolates	No. of Non- <i>mcr</i> Isolates	Total
1	AMP-ENR-PIP-TE-C-CN-S-AK	5	1	0	0.89%
2	AMP-ENR-PIP-TE-C-CN-S	5	2	0	1.78
3	AMP-ENR-PIP-TE-C-CN	5	1	0	0.89
4	AMP-CRO-PIP-TE-C-CN-S	5	1	0	0.89
5	AMP-CRO-PIP-TE-C-CN	5	2	0	1.78
6	AMP-ENR-PIP-TE-C	4	1	2	1.78
7	AMP-PIP-TE-C-CN-S	4	5	2	1.78
8	AMP-PIP-TE-C-CN	4	1	2	1.78
9	AMP-PIP-TE-C-S	4	10	4	3.57
10	AMP-TE-C-CN	4	4	0	3.57
11	AMP-TE-C-S	4	1	2	1.78

Table 2. Cont.

Pattern	Profile	No. of Drug Classes	No. <i>mcr</i> Isolates		No. of Non- <i>mcr</i> Isolates		Total
12	AMP-ENR-PIP-TE	3	1	0.89	0	0	0.89
13	AMP-ENR-PIP-C	3	0	0	1	0.89	0.89
14	AMP-ENR-TE-C	3	1	0.89	0	0	0.89
15	AMP-PIP-TE-C	3	11	9.82	1	0.89	10.71
16	AMP-PIP-TE-CN	3	2	1.78	2	1.78	3.57
17	AMP-PIP-TE-S	3	5	4.46	2	1.78	6.25
18	AMP-PIP-C-S	3	1	0.89	0	0	0.89
19	AMP-PIP-C-CN-S	3	0	0	2	1.78	1.78
20	AMP-TE-C	3	9	8.03	1	0.89	8.921
21	AMP-TE-CN	3	1	0.89	0	0	0.89
22	AMP-TE-S	3	0	0	3	2.67	2.67
Total			60	53.57%	24	21.42	75%

AK—amikacin; AMP—ampicillin; C—chloramphenicol; ENR—enrofloxacin, CN—gentamicin, PIP—piperacillin, S—streptomycin, CRO—ceftriaxone.

2.4. Detection of Antimicrobial Resistance Gene

The distribution of antimicrobial resistance (AMR) genes among the studied isolates showed a significant deviation from a uniform expectation ($\chi^2 = 162.04$, $df = 12$, $p < 0.05$), indicating a substantial heterogeneity in resistance gene prevalence. Among β -lactamase genes, *ampC* and *bla*_{TEM} were detected at the highest frequencies, each present in 93.3% of isolates (95% CI: 0.787–0.982), whereas *bla*_{SHV} and *bla*_{OXA} were not detected in any isolate. For tetracycline resistance, *tetA* and *tetB* were observed in 26.7% (95% CI: 0.142–0.444) and 20.0% (95% CI: 0.095–0.373) of isolates, respectively, while *tetC* was absent. Within the phenicol class, *cmlA* was highly prevalent (73.3%; 95% CI: 0.556–0.858), whereas *cat1* was not detected. Aminoglycoside resistance determinants were also common, with *aadA* detected in 86.7% (95% CI: 0.703–0.947) and *aphA1* in 56.7% (95% CI: 0.392–0.726) of isolates. In contrast, *aad3I* was absent, and *aad3IV* was observed at a low frequency (3.3%; 95% CI: 0.006–0.167) (Table 3).

Table 3. Antimicrobial resistance gene profiles of *E. coli* isolates ($n = 30$).

Class	Gene	Positive (n)	Proportion	95% CI
Beta-lactam	<i>ampC</i>	28	0.933	0.787–0.982
	<i>bla</i> _{TEM}	28	0.933	0.787–0.982
	<i>bla</i> _{SHV}	0	0.000	0.000–0.114
	<i>bla</i> _{OXA}	0	0.000	0.000–0.114
Tetracycline	<i>tetA</i>	8	0.267	0.142–0.444
	<i>tetB</i>	6	0.200	0.095–0.373
	<i>tetC</i>	0	0.000	0.000–0.114
	<i>cat1</i>	0	0.000	0.000–0.114
Phenicol	<i>cmlA</i>	22	0.733	0.556–0.858
	<i>aadA</i>	26	0.867	0.703–0.947
Aminoglycosides	<i>aphA1</i>	17	0.567	0.392–0.726
	<i>aad3I</i>	0	0.000	0.000–0.114
	<i>aad3IV</i>	1	0.033	0.006–0.167

An assessment of the AMR gene distribution across *mcr* genotypes revealed distinct co-occurrence patterns (Figure 3). Isolates harboring *mcr-1* exhibited the highest level of multidrug resistance gene co-selection, particularly for *ampC* and *bla*_{TEM} (60.0% each), *tetA* (23.3%), *cmlA* (46.7%), *aadA* (20.0%), *aphA1* (36.7%), and *aad3-IV* (3.3%). The *mcr-3* genotype also showed moderate AMR gene associations, with *ampC* and *bla*_{TEM} detected in 30.0% of isolates, and several additional determinants, including *tetA* (6.7%), *tetB* (10.0%),

cmlA (16.7%), *aadA* (23.3%), *aphA1* (23.3%), and *aad3-IV* (3.3%). In contrast, the isolates carrying *mcr-4*, *mcr-5*, *mcr-6*, and *mcr-7* lacked all of the screened β -lactam, tetracycline, phenicol, and aminoglycoside resistance determinants. The *mcr-8* genotype displayed a limited co-occurrence, with only low-frequency detection of *ampC*, *tetA*, *cmlA*, and *aadA* (all 3.3%). Meanwhile, *mcr-9* was associated with moderate prevalence of several genes, including *ampC* (26.7%), *bla_{TEM}* (23.3%), *cmlA* (20.0%), and *aphA1* (16.7%). Together, these findings demonstrated that isolates carrying *mcr-1* and *mcr-3* harbored a wider range of co-occurring AMR genes, whereas other *mcr* variants showed minimal coselection of resistance determinants. However, this difference was not statistically significant with Fisher's Exact test ($p = 0.955$).




Figure 3. Heatmap of AMR genes in a 30-isolate subset of *mcr*-encoding *E. coli* from a swine slaughterhouse. Rows denote *mcr* subgroups; columns list AMR genes grouped by drug class. Cells display the percentage of all 30 isolates positive for each gene within each *mcr* subgroup (darker shading = higher prevalence). We did not detect: *bla_{SHV}*, *bla_{OXA}*, *tetC*, *catI*, and *aad3-I*. Fisher's Exact test for frequency data with simulated p -value (based on 2000 replicates); $p = 0.955$.

2.5. Detection of Virulence Gene in *E. coli*

We found the differences in the proportion of *E. coli* pathotypes. A high detection rate was found in Enteropathogenic *E. coli* (EPEC), which is encoded by the *eae* and *bfp* genes. The highest prevalence was in the *eae* gene, with 83/112 isolates (74.10%). On the other hand, the *bfp* gene showed the lowest prevalence, with 1/112 isolates (0.89%). Enterotoxigenic *E. coli* (ETEC) showed low prevalence (less than 2% each). The pathogenic *lt* (heat-labile toxin) gene and *stII* (heat-stable toxin) gene were detected in 2/112 isolates (1.78%). Moreover, Enteroinvasive *E. coli* (EIEC) was encoded by *virF* and *ipaH*. The *virF* gene was detected in 2/112 isolates (1.78%), while the *ipaH* gene was not detected (0%). Similarly, Shiga Toxin-Producing *E. coli* (STEC: *stx-1* and *stx-2*) and Enteroaggregative *E. coli* (EAEC: *aafII*) were not detected in our study. We also detected the *eae*AO157:H7 with 10/112 isolates (8.92%). A Chi-square goodness-of-fit test demonstrated a significant difference in the distribution of virulence genes ($\chi^2 = 802.18$, $p < 0.001$), with *uidA* and *eae* being the predominant markers (Table 4).

The *mcr E. coli* isolates were found to harbor virulence genes. The EPEC-type markers dominated the virulence profile of *mcr* carriers (Figure 4). The *eae* gene was the most detected gene found in *mcr-1* (46.34%), *mcr-9* (29.27%), and *mcr-3* (23.17%). Also, we sporadically detected *mcr-4/7/8* (each 1.22%). However, there was no *mcr-2/5*. In addition, the *bfp* gene was rare ($\leq 1.22\%$, detected only in *mcr-3*). For STEC markers, the detection rate was low, with *stx-2* at 2.44% in *mcr-1*, at 1.22% in *mcr-3*, and *stx-1* at 0% in *mcr-1-9*.

Table 4. Prevalence of pathotype *E. coli* from swine slaughterhouse.

Detection	Target Genes	No. of the Isolates	<i>p</i> -Value
<i>E. coli</i>	<i>uidA</i>	112/124 (90.32%)	<i>p</i> < 0.001
STEC	<i>stx-1</i>	0/112 (0%)	
	<i>stx-2</i>	0/112 (0%)	
EPEC	<i>bfp</i>	1/112 (0.89%)	
	<i>eae</i>	83/112 (74.10%)	
ETEC	<i>lt</i>	2/112 (1.78%)	
	<i>stII</i>	2/112 (1.78%)	
EIEC	<i>virF</i>	2/112 (1.78%)	
	<i>ipaH</i>	0/112 (0%)	
EAEC	<i>aafII</i>	0/112 (0%)	
O157:H7	<i>eaeAO157:H7</i>	10/112 (8.92%)	

Note: Percentages are calculated from 112 *E. coli* isolates. Chi-square goodness-of-fit test demonstrated a significant difference in the distribution of virulence genes ($\chi^2 = 802.18$, $p < 0.001$), with *uidA* and *eae* being the predominant markers.




Figure 4. Pathotype-associated genes among *mcr*-encoding *E. coli* from swine slaughterhouse samples (N = 82). Heatmap cells show the percentage of isolates within each *mcr* subgroup carrying the indicated gene (darker shading = higher prevalence). Panels: EPEC (*eae*, *bfp*), STEC (*stx-1*, *stx-2*), EIEC (*virF*, *ipaH*), ETEC (*lt*, *stII*), EAEC (*aafII*), and O157:H7-specific *eaeAO157:H7*. Fisher's Exact test for frequency data with simulated *p*-value (based on 2000 replicates); $p = 0.864$.

For ETEC markers, the detection rate was also low, with *stII* at 1.22% and *lt* at 0% in *mcr-1*. The EAEC *aafII* was not detected. Furthermore, the detection of the O157:H7-specific *eaeAO157:H7* gene was low, with 4.88% in *mcr-1*, 3.66% in *mcr-3*, and 6.10% in *mcr-9*. Yet, the EIEC targets (*virF*, *ipaH*) were not detected. The relationship between pathotype and *mcr E. coli* was not significantly different ($p = 0.864$).

2.6. Genome Characteristics of *E. coli* Isolates Based on Whole Genome Sequencing

Whole genome sequencing was performed on five representative isolates with the most pronounced antimicrobial resistance phenotypes (EMCR1–EMCR5), generating high-quality assemblies with a deep sequencing coverage (455–584×), ensuring reliable genomic characterization. The total number of raw reads obtained for each isolate ranged from 6.9 to 9.2 million, resulting in assembled genome sizes between 4.49 and 5.18 Mb, which is consistent with the typical genome size of *E. coli*. Assembly quality metrics also indicated generally good contiguity, with N50 values ranging from 47,716 to 108,063 bp and N75 values from 19,939 to 44,622 bp. The number of contigs varied among isolates (115–362), reflecting differences in assembly fragmentation, likely due to a variation in sequencing

depth, read quality, or genome complexity. All genomes had GC contents around 50.5%, which aligned with the expected GC% for *E. coli* (Table 5).

Table 5. Genome characteristics and accession numbers of *E. coli* strains.

ID	Depth of Coverage	Totals Raw Reads (M)	Genome Size (bp)	No. of Contigs	GC (%)	N50 (bp)	N75 (bp)
EMCR1	455	6.895	4,675,856	115	50.59	108,063	44,622
EMCR2	534	9.228	5,181,179	362	50.51	47,716	19,939
EMCR3	584	8.546	4,495,920	149	50.81	72,472	41,866
EMCR4	581	9.057	4,764,291	193	50.61	66,249	35,854
EMCR5	572	8.827	4,744,383	149	50.77	76,012	43,569

2.7. Presence of MLST by Whole-Genome Sequencing

Whole genome sequencing based MLST analysis showed that the five *E. coli* isolates belonged to distinct sequence types, reflecting broad genetic diversity. EMCR1 was classified as ST877, which is associated with the ST86 clonal complex. EMCR2 belonged to ST206 and corresponded to the ST206 clonal complex. EMCR3 was identified as ST542, a sequence type that was not assigned to any currently defined clonal complex. Similarly, EMCR4 was classified as ST2935, which also lacked an established clonal-complex designation. In contrast, EMCR5 belonged to ST48, a member of the widely distributed ST10 clonal complex (Figure 5).

		EMCR1 ST877	EMCR2 ST206	EMCR3 ST542	EMCR4 ST2935	EMCR5 ST48
ST type Clonal complex		ST86 Cplx	ST206 Cplx	-	-	ST10 Cplx
V i r u l e n c e g e n e	<i>AslA</i>					
	<i>amr</i>					
	<i>astA</i>					
	<i>cif</i>					
	<i>colE2-like</i>					
	<i>colE6</i>					
	<i>csgA</i>					
	<i>eae-b04-delta</i>					
	<i>espA</i>					
	<i>espF</i>					
	<i>espJ</i>					
	<i>etpD</i>					
	<i>fdeC</i>					
	<i>fimH</i>					
	<i>fyuA</i>					
	<i>gad</i>					
	<i>hlyE</i>					
	<i>hlyA</i>					
	<i>irp2</i>					
	<i>lpfA</i>					
	<i>katP</i>					
	<i>nleA</i>					
	<i>nleB</i>					
	<i>nlpI</i>					
	<i>ompT</i>					
	<i>terC</i>					
	<i>tir</i>					
	<i>traJ</i>					
	<i>traT</i>					
	<i>yehA</i>					
	<i>yehB</i>					
	<i>yehC</i>					
	<i>yehD</i>					

Figure 5. Genomic profiles of five *E. coli* isolates showing virulence gene content derived from whole-genome sequencing in orange.

2.8. Virulence Gene Detection by Whole-Genome Sequencing

The WGS based assessment of the virulence genes demonstrated a marked variation in virulence gene profiles among the five *E. coli* isolates. EMCR1 carried a moderate set of genes, including adhesion-related genes (*csgA*, *fdeC*, and *lpfA*), stress- and survival-associated markers (*hlyE*, *nlpI*, *ompT*, and *terC*), and the *yehA*–*yehD* gene cluster. EMCR2 displayed the most extensive virulence profile, harboring multiple adhesins (*AslA*, *csgA*, *fdeC*, and *fimH*), enterotoxin and effector genes (*astA*, *cif*, *espA*, *espF*, *espJ*, *tir*, *nleA*, and *nleB*), siderophore-associated genes (*fyuA* and *irp2*), and several secretion- and plasmid-associated genes (*colE2-like*, *etpD*, *traJ*, and *traT*). EMCR3 possessed a smaller but diverse set of virulence genes, including *AslA*, *csgA*, *fdeC*, *fimH*, *hlyE*, *nlpI*, and the *yeh* gene cluster. EMCR4 contained *AslA*, *colE6*, *csgA*, *fimH*, *hlyE*, *nlpI*, *terC*, and several *yeh* genes, indicating a limited but functionally relevant virulence repertoire. We revised this sentence as: EMCR5 was found adhesins genes (*AslA*, *csgA*, *fdeC*, and *fimH*), a toxin-associated gene (*hlyE*), a regulatory gene (*anr*), stress-response marker genes (*nlpI* and *terC*), plasmid-related genes (*traJ* and *traT*), and the *yehA*–*yehD* cluster. Overall, the isolates exhibited a substantial heterogeneity in the virulence content, with EMCR2 showing the broadest array of virulence determinants and the remaining isolates carrying more restricted but distinct sets of the virulence genes (Figure 5).

2.9. Presence of AMR Genes by Whole-Genome Sequence

Analysis of antimicrobial resistance (AMR) determinants among the five EMCR isolates revealed substantial variation in both genetic profiles and corresponding phenotypic resistance patterns. EMCR1 carried aminoglycoside-modifying enzyme genes *aph6-Id* and *aph3-Id*, the β -lactamase *bla*_{TEM-1B}, the plasmid-mediated quinolone resistance gene *qnrS1*, and the tetracycline resistance determinant *tetM*. These genotypes were consistent with its phenotypic resistance to ampicillin, piperacillin, streptomycin, tetracycline, and chloramphenicol (AMP-PIP-S-TE-C). EMCR2 exhibited the most extensive AMR repertoire, including multiple aminoglycoside resistance genes (*aadA1*, *aadA2*, *aac3-IId*, *aph6-Id*, *aph3''-Ib*, and *aph3''-Ia*), the β -lactamase *bla*_{TEM-1B}, the colistin resistance gene *mcr-1.1*, macrolide–lincosamide–streptogramin genes (*mphA* and *ermB*), phenicol resistance genes (*cmlA1*, *flor*), sulfonamide resistance genes (*sul1* and *sul3*), and multiple tetracycline resistance genes (*tetM*, *tetX4*, and *tetA*), along with trimethoprim resistance genes (*dfrA12* and *dfrA5*). This broad AMR gene profile corresponded with resistance to ampicillin, pirlimycin, streptomycin, tetracycline, chloramphenicol, and gentamicin (AMP-PIP-S-TE-C-CN). EMCR3 possessed genes associated with aminoglycoside resistance (*aadA1*), phenicol resistance (*floR*), plasmid-mediated quinolone resistance (*qnrS13*, *OqxA*, and *OqxB*), tetracycline resistance (*tetA*), and folate-pathway resistance (*dfrA12* and *dfrA14*). The observed genotype aligned with resistance to AMP-PIP-S-TE-C. EMCR4 harbored multiple aminoglycoside resistance genes, including *aph6-Id*, *aph3''-Id*, *aac3-IId*, and *aph3'-Ia*, as well as a diverse set of β -lactamases (*bla*_{TEM-220}, *bla*_{TEM-135}, *bla*_{TEM-126}, *bla*_{TEM-106}, and *bla*_{TEM-1B}). Additionally, it encoded *mcr-1.1*, *qnrS1*, *sul1*, and tetracycline resistance genes (*tetM* and *tetA*), along with *dfrA5*. These determinants were reflected in its phenotype, showing resistance to AMP-PIP-S-TE-C-CN. Finally, EMCR5 carried *aadA1*, *aadA2*, *bla*_{TEM-1B}, *cmlA1*, and tetracycline and trimethoprim resistance genes (*tetM*, *tetA*, and *dfrA12*), consistent with resistance to AMP-PIP-S-TE-C. Overall, the concordance between AMR genotypes and phenotypes across isolates supports the functional expression of the detected resistance determinants (Figure 6).




Figure 6. Genomic profiles of five *E. coli* isolates showing antimicrobial resistance genes derived from whole-genome sequencing in blue.

2.10. Plasmid Replicon Detection

Whole-genome sequencing identified a diverse range of plasmid replicon types among the EMCR isolates, reflecting substantial plasmid-mediated genomic plasticity and a high potential for horizontal gene transfer. EMCR1 carried three replicon groups—IncFIB(K), ColE10, and IncX1—all of which are frequently associated with Enterobacterales plasmids, involved in antimicrobial resistance dissemination. EMCR2 exhibited the most extensive plasmid repertoire, comprising IncHI2, IncHI2A, IncFIA(HI1), IncFIB(AP001918), IncFIB(K), IncFII, IncN, and IncX1, together with multiple Col-type elements (Col156, ColRNAI, and Col440II). This combination of large conjugative plasmids and small mobilizable plasmids is characteristic of highly transmissible multidrug-resistant lineages. EMCR3 harbored IncFIB(K), IncFIA(HI1), and IncX1, indicating the presence of well-recognized conjugative backbones that are commonly found in clinically relevant Enterobacterales. EMCR4 contained replicons IncHI2, IncHI2A, Col156, IncQ1, and p0111, a profile consistent with plasmid groups known to accommodate a wide variety of acquired-resistance determinants. EMCR5 carried multiple replicon types, including IncFIC(FII), IncX1, p0111, IncFIB(AP001918), Col440I, IncFIA(HI1), and IncFIB(K). This reflected the co-existence of several large conjugative plasmids together with smaller Col-type plasmids within a

single genome. Collectively, the identification of plasmid families, such as IncF, IncHI2, IncX1, and IncN, across these isolates underscores the prominent role of plasmid-edited mechanisms in shaping the genomic architecture of the EMCR strains and supports their capacity for efficient transmission of antimicrobial resistance determinants. Collectively, the WGS data indicate that the EMCR isolates showed highly plastic genomes shaped by extensive plasmid-mediated gene acquisition. Isolates with the broadest AMR and virulence profiles, particularly EMCR2 and EMCR4, also harbored multiple large conjugative plasmids (e.g., IncHI2, IncF, and IncN), suggesting that resistance and virulence determinants are embedded within mobile genomic backbones. The diversity of sequence types, including lineages previously reported in both animal and human settings, further supports the role of slaughterhouse environments as convergence points for heterogeneous *E. coli* populations. Together, these genomic features highlight the potential for horizontal dissemination and persistence of high-risk *E. coli* genotypes along the food chain (Figure 7).

		EMCR1	EMCR2	EMCR3	EMCR4	EMCR5
		ST877	ST206	ST542	ST2935	ST48
		ST86 Cplx	ST206 Cplx	-	-	ST10 Cplx
P l a s m i d R e p l i c o n	<i>Col156</i>					
	<i>IncHI2</i>					
	<i>IncHI2A</i>					
	<i>IncFIB(AP001918)</i>					
	<i>IncFIA(HI1)</i>					
	<i>IncFIB(K)</i>					
	<i>IncFIB(K)8</i>					
	<i>ColE10</i>					
	<i>Col156</i>					
	<i>ColRNAI</i>					
	<i>IncX1</i>					
	<i>IncFIB(K)</i>					
	<i>IncFIC(FII)</i>					
	<i>IncFII</i>					
	<i>IncQ1</i>					
	<i>Col440I</i>					
	<i>Col440II</i>					
	<i>IncHI2</i>					
	<i>IncN</i>					
	<i>IncX1</i>					
	<i>p0111</i>					

Figure 7. Genomic profiles of five *E. coli* isolates showing plasmid replicon types derived from whole-genome sequencing in green.


2.11. Analysis of Secondary Metabolite Biosynthesis Gene Clusters

Whole-genome analysis using antiSMASH version 7.0 (<https://antismash.secondarymetabolites.org>, accessed on 1 November 2024) identified multiple secondary metabolite biosynthesis gene clusters across all five isolates (Figure 6). EMCR1 contained two clusters, comprising a complete NRP-metallophore/NRPS cluster with 100% similarity to the enterobactin biosynthetic pathway, together with a low-similarity thiopeptide cluster (14%). EMCR2 exhibited the greatest diversity, harboring four clusters, including an enterobactin-like NRPS cluster (90%); an NRPS–T1PKS hybrid cluster, showing partial similarity to the yersiniabactin system (17%); and two additional clusters of the thiopeptide and RiPP showed low similarity (~14%). EMCR3 carried one thiopeptide cluster (14%) and one NRPS cluster, both lacking close matches to known references, indicating potentially divergent or uncharacterized secondary metabolite pathways. EMCR4 contained a low-

similarity thiopeptide cluster (14%) together with a fully conserved enterobactin-associated NRPS cluster (100%). EMCR5 similarly encoded one thiopeptide cluster (14%) and one enterobactin-like NRPS cluster with 100% similarity.


2.12. Compare Genome Mapping

Comparative circular genome mapping of the five *E. coli* EMCR isolates (EMCR1–EMCR5) showed a largely conserved chromosomal backbone (~5 Mb scale) with similar CDS density and generally stable GC content/GC-skew profiles, consistent with shared core genome organization. All genomes displayed multiple annotations linked to reduced antimicrobial accumulation, including Acr-family efflux components (e.g., *acrB/acrF*) and Mdt-family multidrug transporters, suggesting a common intrinsic capacity for tolerance to diverse toxic compounds. However, genome plasticity differed among strains: EMCR1 contained a clearly annotated Tn3-family transposase (*Tn2*), and EMCR4 also showed a Tn3-family/IS-associated transposase feature, supporting strain-specific horizontal acquisition or rearrangement potential. CRISPR–Cas content varied markedly across isolates, with EMCR1 showing a single Cas cluster, EMCR3 carrying a CAS-Type IIE cluster, EMCR2 and EMCR4 containing both a Cas cluster and a CAS-Type IIE annotation, and EMCR5 encoding the most extensive defense repertoire, including CAS-Type IIE plus additional Type I-associated cas annotations (e.g., *cas3*). Together, these data indicate that while EMCR isolates share conserved efflux or transport features relevant to antimicrobial tolerance, they differ in mobile-element signatures and CRISPR–Cas defenses that may influence their propensity to acquire or restrict additional resistance determinants (Figure 8).




(A) Genome visualization of the isolate EMCR1

Figure 8. Cont.




(B) Genome visualization of the isolate EMCR2




(C) Genome visualization of the isolate EMCR3

Figure 8. Cont.



(D) Genome visualization of the isolate EMCR4



(E) Genome visualization of the isolate EMCR5

Figure 8. Genome visualization of five *E. coli* isolates EMCR1-EMCR5 (A–E) with details of antimicrobial resistance gene (AMR) region, coding sequence (CDS) region, contigs, GC content and skewness (GC), mobile genetic element (MGE) region, and Cas cluster.

3. Discussion

The high prevalence of colistin-resistant *E. coli* observed in this study is consistent with previous reports from swine production systems in Southeast Asia, where colistin has been frequently used as a growth promoter and therapeutic agent [27,28]. A study by

Nguyen et al. (2022) in Vietnam found a similar prevalence (88%) of colistin-resistant *E. coli* in swine farms, highlighting the widespread occurrence of resistance in food-producing animals [29]. The dominance of *mcr-1* among our isolates aligns with global patterns, as *mcr-1* remains the most frequently detected plasmid-mediated colistin resistance gene in swine, pork products, and farm environments worldwide [30,31]. The additional detection of *mcr-3* and *mcr-9* further supports other emerging reports on the multiple *mcr* variants co-circulating in swine systems. The patterns are more likely driven by long-term antimicrobial exposure and complex plasmid-mediated gene-transfer dynamics [32,33]. The coexistence of multiple *mcr* genes within the same isolate, such as *mcr-1/mcr-3* and *mcr-1/mcr-9* combinations, suggests active horizontal gene-transfer events and the accumulation of diverse resistance determinants on multireplicon plasmids. The phenomenon has also been described in swine-associated *E. coli* in Thailand, China, and Spain [34–36]. These multi-*mcr* plasmids have been shown to persist in bacterial populations even after a reduction or a withdrawal of colistin use due to co-selection from other antimicrobials and heavy metals commonly used in swine feed formulations [13,37]. The presence of less common variants *mcr-4*, *mcr-7*, and *mcr-8*, although at low frequencies, indicates an ongoing diversification of *mcr* reservoirs within the swine gut microbiome. Since slaughterhouses serve as critical junction points where fecal contamination, carcass surfaces, and the environment intersect, the detection of diverse *mcr*-positive isolates at this stage raises substantial concern regarding potential spillover into the food chain, farm workers, and downstream environments [38,39]. Overall, the high prevalence and diversity of *mcr*-mediated colistin resistance in this setting highlight an urgent need for targeting antimicrobial stewardship in swine production systems. Strengthened regulations of colistin use, enhanced hygiene measures in slaughterhouses, and routine genomic monitoring of *mcr*-carrying plasmids are essential steps toward mitigating the transmission of colistin-resistant *E. coli*. Given the established evidence of animal-to-human transmission of *mcr*-positive strains through direct contact, contaminated meat, and environmental pathways, these findings underscore the importance of integrated One Health strategies across veterinary and public-health sectors [36,40]. Although broth microdilution is the reference method recommended for colistin susceptibility testing, it was not included in the present study. Consequently, the absence of MIC data limits the ability to assess the level of phenotypic resistance. Nevertheless, the combination of selective phenotypic screening and molecular detection was appropriate for the primary objective of this study, which focused on the genomic characterization of *mcr*-harboring *E. coli*. Future studies incorporating standardized MIC determination would be beneficial to further strengthen genotype–phenotype correlations.

Among the aminoglycosides, the isolates remained highly susceptible to amikacin (resistance in 2.44% of *mcr*-positive isolates and 0% in non-*mcr* isolates), while gentamicin resistance showed moderate frequency (26.83% vs. 33.33%). Streptomycin resistance was observed (40.24% vs. 56.67%). The results align with the previous study, which shows the prevalence of streptomycin resistance in livestock farms [41]. Enrofloxacin resistance was relatively low (~10–11% across groups), whereas tetracycline resistance was high (~89% overall), reflecting widely reported resistance trends in livestock production systems [42]. These findings emphasized the need for antibiotic stewardship and surveillance in animal husbandry, especially in regions where antibiotics are frequently used without strict regulatory control. The high frequency of MDR patterns in *E. coli* from swine aligned with global trends of increasing resistance in livestock-associated bacteria. A study by Wu et al. (2018) found that 70% of *E. coli* isolates from swine in China showed MDR [43], while in Thailand, MDR rates exceeding 60% have been reported [44,45]. The extensive use of antibiotics in animal farming, particularly for growth promotion and disease prevention, has been implicated as a major driver of this resistance [46]. These results underscore an urgent need for enhanced antimicrobial steward-

ship in livestock sectors, including stricter regulations on antibiotic use, routine surveillance, and the promotion of alternative disease management strategies to curb the emergence and dissemination of MDR pathogens. Colistin resistance mediated by plasmid-borne *mcr* genes represents a major public health concern due to the drug's role as a last-resort antibiotic for multidrug-resistant Gram-negative infections [28,47].

The detected ARGs span several major antibiotic classes, including aminoglycosides, β -lactams (including extended-spectrum β -lactamase [ESBL] and *ampC* β -lactamase), tetracyclines, and phenicols, which are commonly used in veterinary practice. The most prevalent resistance genes identified were *aadA*, associated with aminoglycoside resistance, and *ampC*, a β -lactamase that confers resistance to cephalosporins and penicillin. The widespread presence of these genes is consistent with prior studies that report the high detection rates of *aadA* and *ampC* genes in *E. coli* isolated from livestock, particularly in intensively farmed swine [47,48]. These findings support concerns over the dissemination of plasmid-mediated *ampC* β -lactamases, which can reduce the efficacy of β -lactam antibiotics in both veterinary and human medicine [49]. The results of the *bla*_{TEM} gene aligned with the report on *E. coli* in swine, especially in association with mobile genetic elements that facilitate its horizontal transfer [43]. Its prevalence highlights the ongoing selection pressure exerted by β -lactam usage in animal agriculture.

Moderate frequencies were observed for *cmlA* and *bla*_{SHV}, representing resistance to phenicols and β -lactams, respectively. The *cmlA* gene encodes a chloramphenicol efflux pump and has previously been linked to resistance in both swine and poultry *E. coli* isolates [49,50]. In contrast, *bla*_{OXA}, *tetA*, and *tetB* were detected at lower frequencies. These genes are responsible for resistance to β -lactams (OXA-type β -lactamases) and tetracyclines, respectively. The relatively low prevalence of tetracycline resistance genes was surprising, considering the extensive historical use of tetracyclines in swine farming. However, regional differences in antibiotic usage policies or horizontal gene transfer dynamics may explain these variations [51,52]. Importantly, no isolates carried the *cat1*, *aac*(3)-I, *aac*(3)-IV, or *tetC* genes. The absence of these genes suggests either limited use of corresponding antibiotics or their replacement by more dominant resistance mechanisms in this population. The lack of detection aligns with previous reports, showing that the prevalence of specific resistance genes can fluctuate based on antimicrobial usage patterns, geographical location, and plasmid compatibility [53]. Collectively, these findings emphasized the genetic diversity of the antimicrobial resistance mechanisms in *E. coli* at the slaughterhouse level and highlight the necessity for continuous monitoring and responsible antimicrobial stewardship in animal husbandry.

A variety of virulence genes were found in *E. coli* in this study. Interestingly, the EPEC was the most prevalence, this result was agreed with previous studies [54,55], together with the extremely low detection of *bfp*, strongly suggests that most isolates belong to atypical EPEC (aEPEC; *eae*⁺/*bfp*[−]) rather than typical EPEC. This is consistent with recent work, indicating that aEPEC is currently the predominant EPEC subtype in both humans and animals and is recognized as a major cause of diarrhea, especially in low- and middle-income settings [56]. In contrast to the predominance of *eae*, ETEC markers (*lt* and *stII*) were detected in only 2/112 isolates (1.78% each), and STEC markers (*stx1*, *stx2*), as well as EAEC (*aafII*) and EIEC (*ipaH*). This is noteworthy because ETEC and STEC are classically considered the main enteric pathotypes in swine, particularly in neonatal and post-weaning diarrhea [57]. Many published swine studies target clinically diarrheic piglets or farm outbreaks, in which ETEC and STEC are enriched [58]. In contrast, the present work focuses on slaughterhouse isolates, which are more likely to originate from subclinical colonized animals and from environmental contamination along the processing line. Under such conditions, EPEC/aEPEC-like *E. coli* may outnumber classical enterotoxigenic or

toxigenic strains. However, the positive detection of the *eae*AO157:H7 gene showed a higher prevalence than a previous study [59]. Among the *mcr*-positive *E. coli* and virulence genes, this study found that EPEC-type markers dominated, which disagreed with the study by Göpel et al. [60]. The previous study detected the highest frequency of the ETEC/STEC hybrid. However, our results align with the highest frequency of the *mcr*-1 detection [60]. From One Health perspectives, the convergence of the critical last-resort resistance (*mcr*) and intestinal virulence (*eae*) in slaughterhouse isolates is particularly alarming. It indicates that slaughterhouse environments may act as hubs where resistant and virulent *E. coli* genotypes mix and disseminate along the food chain, especially if hygiene and antimicrobial stewardship are suboptimal [61]. The high prevalence of *eae* among slaughterhouse isolates highlights the potential role of subclinically colonized animals as reservoirs of intestinally adherent *E. coli*. Given that *eae*-positive strains are capable of efficient intestinal colonization in humans, their presence in slaughterhouse environments raises concerns regarding food-chain contamination and zoonotic transmission. From a One Health perspective, the coexistence of intestinal virulence determinants and antimicrobial resistance in these isolates underscores the importance of strengthened hygiene control and surveillance at the animal–food–human interface.

Whole-genome sequencing (WGS) of five *E. coli* isolates (EMCR1–EMCR5) was conducted using Illumina technology, yielding high-quality assemblies with genome sizes ranging from 4.49 to 5.18 Mb and GC content between 50.51% and 50.81%, consistent with typical *E. coli* genomes [62,63]. The depth of coverage (455*–584*) and total raw reads (6.9–9.2 million) ensured reliable sequencing performance, comparable to other high-throughput *E. coli* studies [64]. Assembly metrics, such as N50 (47,716–108,063 bp) and contig counts (115–362), indicated moderate variation in genome continuity, potentially influenced by repetitive elements or strain complexity [65]. Multilocus sequence typing (MLST) based on WGS revealed diverse sequence types (STs) and clonal complexes (CCs), including ST877/CC86 and ST48/CC10, both previously linked to antimicrobial resistance and pathogenicity [66,67]. EMCR3 displayed genetic heterogeneity (ST542). However, EMCR4 (ST2935) may represent an under characterized lineage. The genomic diversity identified highlights the ecological adaptability and potential public health relevance of these isolates. WGS analysis revealed a diverse set of virulence genes among the five *E. coli* isolates. EMCR1–EMCR5 harbored typical virulence-associated genes, such as *astA*, *csgA*, *fdeC*, *fimH*, *hlyE*, *ompT*, and the *yeh* operon, associated with adhesion and biofilm formation [68]. EMCR2 exhibited the broadest virulence profile, including *eae*, *espA*, *tir*, *nleA/nleB*, and *cif*, consistent with an EPEC-like pathogenic potential [69].

Additional genes, such as colicin genes, *katP*, and yersiniabactin system (*irp2/fyuA*), suggest enhanced oxidative stress tolerance and iron acquisition [65]. The presence of *traJ/traT* in EMCR2 and EMCR5 reflects the potential for horizontal gene transfer and serum resistance. The antimicrobial resistance gene (ARG) profiles showed broad resistance across isolates, particularly in EMCR2 and EMCR4, which harbored *mcr*-1.1 and multiple β -lactamase genes (*bla*_{TEM} variants). Also, a diverse resistance determinant against aminoglycosides, macrolides, tetracyclines, and sulfonamides aligns with reports of MDR *E. coli* from swine in Asia [30,47]. The concordance between genotype and phenotype across all isolates supports WGS as a reliable predictor of resistance patterns [70]. The detection of *mcr*-1.1 highlights a public health concern due to its plasmid-mediated colistin resistance [36].

All isolates carried plasmids with known associations to resistance and virulence. Common replicons included IncFIB(K), IncX1, and Col-type plasmids, consistent with global *E. coli* plasmid patterns [71]. EMCR2 and EMCR5 harbored the most diverse plasmid types, including IncHI2/HI2A, IncFIA, and p0111, which have been linked to ESBL and *mcr* gene dissemination in livestock and clinical settings [72,73]. The broad plasmid content

observed, especially in MDR isolates, underscores their potential for horizontal transfer and persistence in diverse environments.

4. Materials and Methods

4.1. Sample Size and Sampling Techniques

The sample size was calculated using a formula for estimating true prevalence (<https://epitools.ausvet.com.au> (accessed on 2 January 2024)). Owing to reported variability in the prevalence of colistin-resistant *Escherichia coli*, an expected prevalence of 10.4% was used for the calculation. The parameters applied included a test sensitivity of 95%, specificity of 90%, a desired precision of 10%, and a 90% confidence level. Based on these assumptions, a total of 200 fecal samples were collected and analyzed.

4.2. Sample Collection

A total of 200 fecal samples were randomly collected via rectal swabbing from finishing and breeder swine across 20 batches at a slaughterhouse in Nakhon Si Thammarat Province, Southern Thailand, between January and July 2024. All laboratory procedures were conducted at the Research Building of Walailak University. The study was approved by the Walailak University Animal Care and Use Committee (WU-ACUC-66-047) and the Institutional Biosafety Committee (WU-IBC-66-024). Samples were transported in sterile plastic bags within ice boxes to the laboratory and processed for microbiological analysis within one hour of collection.

4.3. *Escherichia coli* Isolation and Confirmation

All samples were analyzed for the presence of colistin-resistant *E. coli*. Approximately 10 g of fecal material was placed into a sterile plastic bag and mixed with 90 mL of Peptone Saline Buffer, containing 0.1% peptone (Oxoid, Hampshire, UK), followed by homogenization using a stomacher. A 10 µL loop of the resulting suspension was inoculated onto MacConkey agar (Oxoid, Hampshire, UK) with 4 mg/L of colistin. The agar plates were then incubated at 37 °C for 24 h [15]. From plates exhibiting bacterial growth, we characterized bacterial colonies by red coloration, smooth spherical morphology, and a diameter >2.5 mm. We selected a colony, subcultured it onto Eosin Methylene Blue (EMB) agar (HiMedia, Mumbai, India), and incubated it at 37 °C for 24 h. Colonies with metallic green sheen on the EMB agar were considered indicative of *E. coli* and were subsequently subcultured onto tryptic soy agar (HiMedia, India) and incubated at 37 °C for an additional 24 h. Polymerase Chain Reaction (PCR) was performed to confirm the identity of each presumptive isolate by targeting the *uidA* gene. Genomic DNA was extracted from all *E. coli*-positive samples using a bacterial genomic DNA extraction kit (Geneaid, New Taipei City, Taiwan), following a previously described protocol [37]. PCR amplification was performed, and the products were confirmed using electrophoresis on a 1.5% agarose gel (Major Science, Irvine, CA, USA). PCR bands were visualized under UV illumination using a G-BOX F3 Gel Documentation System (Syngene, Cambridge, UK). The primer sequences, expected amplicon sizes, and annealing temperatures are detailed in Table 6.

Table 6. Primers are used for the amplification of *E. coli* genes, *mcr*-encode genes, pathotype *E. coli* genes, and antibiotic-resistant genes of *E. coli*.

Target Genes	Primer Sequences	Product Size (bp)	Annealing Temperature	References
<i>uidA</i>	F: 5'-GTCACGCCGTATGTTATTG-3' R: 5'-CCAAAGCCAGTAAAGTAGAAC-3'	530	58	[74]

Table 6. Cont.

Target Genes	Primer Sequences	Product Size (bp)	Annealing Temperature	References
<i>mcr-1</i>	F: 5'-AGTCCGTTTGTCTTGTGGC-3' R: 5'-AGATCCTTGGTCTCGGCTTG-3'	320	58	[75]
<i>mcr-2</i>	F: 5'-CAAGTGTGTTGGTCGCAGTT-3' R: 5'-TCTAGCCCGACAAGCATACC-3'	715	58	[75]
<i>mcr-3</i>	F: 5'-AAATAAAAAATTGTTCCGCTTATG-3' R: 5'-AATGGAGATCCCCGTTTTT-3'	929	58	[75]
<i>mcr-4</i>	F: 5'-TCACTTTCATCACTGCGTTG-3' R: 5'-TTGGTCCATGACTACCAATG-3'	1116	58	[75]
<i>mcr-5</i>	F: 5'-ATGCGGTTGTCTGCATTATC-3' R: 5'-TCATTGTGGTTGTCCTTTTCTG-3'	1644	58	[75]
<i>mcr-7</i>	F: 5'-GTCAGTTACGCCATGCTCAA-3' R: 5'-TTCTTGTGCGCAGAACTGTGG-3'	791	59	[76]
<i>mcr-8</i>	F: 5'-AAACTGAACCCGGTACAACG-3' R: 5'-GCCATAGCACCTCAACACCT-3'	943	59	[76]
<i>mcr-9</i>	F: 5'-GCGGTTGTAAAGGCGTATGT-3' R: 5'-CAAATCGCGGTCAGGATTAT-3'	635	59	[76]
<i>stx-1</i>	F: 5'-CAGTTAATGTGGTGGCGAAGG-3' R: 5'-CACCAGACAATGTAACCGCTG-3'	348	58	[77]
<i>stx-2</i>	F: 5'-ATCCTATTCGCGGAGTTTACG-3' R: 5'-GCGTCATCGTATACACAGGAGC-3'	584	58	[77]
<i>bfp</i>	F: 5'-GGAAGTCAAATTCATGGGGGTAT-3' R: 5'-GGAATCAGACGCAGACTGGTAGT-3'	300	58	[77]
<i>eae</i>	F: 5'-TCAATGCAGTTCCGTTATCAGTT-3' R: 5'-GTAAAGTCCGTTACCCCAACCTG-3'	482	58	[77]
<i>lt</i>	F: 5'-GCACACGGAGCTCCTCAGTC-3' R: 5'-TCCTTCATCCTTTCAATGGCTTT-3'	218	58	[77]
<i>stII</i>	F: 5'-AAAGGAGAGCTTCGTCACATTTT-3' R: 5'-AATGTCCGCTCTGCGTTAGGAC-3'	129	58	[77]
<i>virF</i>	F: 5'-AGCTCAGGCAATGAAACTTTGAC-3' R: 5'-TGGGCTTGATATCCGATAAGTC-3'	618	58	[77]
<i>ipaH</i>	F: 5'-CTCGGCACGTTTTAATAGTCTGG-3' R: 5'-GTGGAGAGCTGAAGTTTCTCTGC-3'	933	58	[77]
<i>aafII</i>	F: 5'-CACAGGCAACTGAAATAAGTCTGG-3' R: 5'-ATTCCCATGATGTCAAGCACTTC-3'	378	58	[77]
<i>eaeAO157:H7</i>	F: 5'-AAGCGACTGAGGTCAC-3' R: 5'-ACGCTGCTCACTAGATGT-3'	473	60	[77]
<i>cat1</i>	F: 5'-AGTTGCTCAATGTACCTATAACC-3' R: 5'-TTGTAATTCATTAAGCATTCTGCC-3'	547	58	[50]
<i>cmlA</i>	F: 5'-CCGCCACGGTGTGTTGTTATC-3' R: 5'-CACCTTGCCGTCATCATTAG-3'	698	58	[50]
<i>aadA</i>	F: 5'-TGATTTGCTGGTTACGGTGAC-3' R: 5'-CGCTATGTTCTCTTGCTTTTG-3'	284	58	[50]
<i>aac(3)-I</i>	F: 5'-ACCTACTCCCAACATCAGCC-3' R: 5'-ATATAGATCTCACTACGCGC-3'	157	58	[50]
<i>aphA-I</i>	F: 5'-ATGGGCTCGCGATAATGTC-3' R: 5'-CTCACCGAGGCAGTTCCAT-3'	600	58	[50]
<i>aac(3)-IV</i>	F: 5'-CTTCAGGATGGCAAGTTGGT-3' R: 5'-TCATCTCGTTCTCCGCTCAT-3'	286	58	[50]
<i>bla_{TEM}</i>	F: 5'-TCGCCGCATACACTATTCTCAGAATGA-3' R: 5'-ACGCTCACCGGCTCCAGATTTAT-3'	445	60	[78]
<i>bla_{OXA}</i>	ACA CAA TAC ATA TCA ACT TCG C AGT GTG TTT AGA ATG GTG ATC	813	60	[79]
<i>bla_{SHV}</i>	F: 5'-ATGCGTTATATTCGCTGTG-3' R: 5'-TGCTTTGTTATTTCGGGCCAA-3'	747	51	[78]
<i>tetA</i>	F: 5'-GTAATTCTGAGCACTGTCCG-3' R: 5'-CTGCCTGGACAACATTGCTT-3'	965	57	[50]
<i>tetB</i>	F: 5'-CTCAGTATTCCAAGCCTTTG-3' R: 5'-ACTCCCCTGAGCTTGAGGGG-3'	414	52	[50]

Table 6. Cont.

Target Genes	Primer Sequences	Product Size (bp)	Annealing Temperature	References
<i>tetC</i>	F: 5'-CCTCCTGCGGGATATCGTCC-3' R: 5'-GGTTGAAGGCTCTCAAGGGC-3'	505	65	[50]
<i>ampC</i>	F: 5'-ATCAAACTGGCAGCCG-3' R: 5'-GAGCCCGTTTATGCACCCA-3'	510	65	[80]

4.4. Antibiotic Susceptibility Testing

Antimicrobial susceptibility testing of all isolates was performed using the disk diffusion method, following the guidelines of the Clinical and Laboratory Standards Institute (CLSI, 2019) [81]. Isolates were initially cultured on Tryptic Soy Agar (TSA) (HiMedia Laboratories, Mumbai, India). Each bacterial suspension was adjusted to match the 0.5 McFarland turbidity standard, and the standardized *E. coli* inoculum was evenly spread onto Mueller–Hinton Agar (MHA) (HiMedia Laboratories, Mumbai, India) using sterile cotton swabs. Antimicrobial disks were then placed on the agar surface, and plates were incubated at 37 °C for 24 h. Susceptibility was assessed against ten antimicrobial agents representing five major classes: beta-lactams (ampicillin, amoxicillin/clavulanic acid, and piperacillin), aminoglycosides (amikacin, gentamicin, and streptomycin), phenicols (chloramphenicol), cephalosporins (ceftriaxone), quinolones (enrofloxacin), and tetracyclines (tetracycline) (Oxoid Ltd., Basingstoke, UK). Multidrug resistance (MDR) was defined as resistance to at least one antimicrobial agent in three or more different antibiotic classes.

4.5. Molecular Detection of Colistin Resistance Genes, Pathotype Genes, and Antimicrobial Resistance Genes

A total of 112 *E. coli* isolates were identified as carrying colistin resistance genes, including *mcr-1*, *mcr-2*, *mcr-3*, *mcr-4*, *mcr-5*, *mcr-7*, *mcr-8*, and *mcr-9*. Multiplex PCR targeting *mcr-1* to *mcr-5* was conducted under the following conditions: initial denaturation at 94 °C for 15 min, followed by 35 cycles of denaturation at 94 °C for 30 s, annealing at 58 °C for 90 s, and extension at 72 °C for 60 s, with a final extension step at 72 °C for 10 min. The detection of *mcr-7*, *mcr-8*, and *mcr-9* was carried out using a separate PCR protocol consisting of initial denaturation at 94 °C for 4 min, followed by 20 cycles of denaturation at 94 °C for 5 s, annealing at 59 °C for 15 s, and a final extension at 72 °C for 5 min. Additionally, the isolates were screened for pathotype-specific genes using PCR amplification. Ten virulence-associated genes were targeted: *eae*, *bfp*, *stx-1*, *stx-2*, *lt*, *stII*, *virF*, *ipaH*, *aafII*, and *eaeAO157:H7*. PCR conditions for pathotype gene detection were conducted as previously described (Table 6). Thirty randomly selected *E. coli* isolates were analyzed for the presence of antibiotic resistance genes using specific primers (Table 6) through PCR, following a previous study. The PCR conditions for amplifying resistance genes included an initial denaturation at 95 °C for 5 min, followed by 30 cycles consisting of denaturation at 95 °C for 35 s, annealing at the appropriate temperature for 45 s, and extension at 72 °C for 1 min. A final extension step was performed at 72 °C for 5 min [20].

4.6. Whole-Genome Sequencing

Five *E. coli* isolates exhibiting multidrug resistance (MDR) and demonstrating the highest multiple antibiotic resistance (MAR) indices were selected for whole-genome sequencing. Genomic DNA was extracted from these representative isolates using a commercial kit (Geneaid, New Taipei City, Taiwan). The quality and concentration of the extracted DNA were evaluated using a microvolume UV-Vis spectrophotometer (ThermoScientific™ NanoDrop™ One, Madison, WI, USA) and further verified by agarose gel

electrophoresis. High-quality DNA samples underwent de novo sequencing, and sequence reads were assembled using Velvet (version 1.2.10). Contig extension was performed with GapFiller (version 1.10), followed by scaffold construction using SSPACE (version 3.0). Protein-coding genes were predicted from the assembled scaffolds using Prodigal (version 2.6.3). Functional annotation of the predicted genes was performed using BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi> (accessed on 1 November 2024)), with significant matches defined by an E-value threshold of less than 0.00001.

4.7. Application of Bioinformatic Tools

Whole-genome sequencing (WGS) was performed using a paired end short read sequencing approach. Raw sequencing reads were quality checked and filtered using AfterQC v0.9.6, including adapter trimming and error correction. De novo genome assembly was conducted using Unicycler v0.5.0 and QUAST v5.0.2. Genome completeness and contamination were evaluated using CheckM v1.1.2, and genome annotation was performed with Prokka v1.14.6. Genome assemblies were further analyzed using web-based bioinformatics tools to confirm *E. coli* identification, determine sequence types, and characterize antimicrobial resistance genes (ARGs), mobile genetic elements (MGEs), and virulence factors (VFs). Species identification was performed using KmerFinder v3.2 (<https://cge.food.dtu.dk/services/KmerFinder/>, (accessed on 1 November 2024)) Multilocus sequence typing (MLST) and clonal-complex assignment were conducted using the PubMLST database (<https://pubmlst.org/> (accessed on 1 November 2024)), based on allelic profiles of seven housekeeping genes (*adk*, *fumC*, *gyrB*, *icd*, *mdh*, *purA*, and *recA*). Antimicrobial resistance genes were identified using ResFinder 4.0 (<https://cge.food.dtu.dk/services/ResFinder/> (accessed on 1 November 2024)) with default thresholds of 90% sequence identity and a minimum alignment length of 60%, including the detection of chromosomal point mutations, following Bortolaia et al. (2020) [82]. The presence of MGEs and their associations with ARGs and VFs were analyzed using MobileElementFinder v1.0.3, as described by Johansson et al. (2021) [83]. Virulence-associated genes were identified using the Virulence Factor Database (VFDB) by applying a conservative BLASTp threshold with an E-value of 1×10^{-10} and a minimum query coverage of 40%, following the approach described by Liu et al. (2022) [84].

4.8. Statistical Analysis

Descriptive statistics were used to summarize the prevalence of *E. coli*, *mcr*-encoding isolates, antimicrobial resistance profiles, resistance genes, and virulence genes. Differences in proportions between groups were analyzed using Fisher's exact test or the Chi-square test, as appropriate. Statistical analyses were performed using R (version 4.3.0), and a *p*-value < 0.05 was considered statistically significant. Binomial 95% confidence intervals (CIs) were calculated using the Wilson score method [85].

5. Conclusions

This study investigated colistin-resistant *Escherichia coli* from swine farms, revealing a high prevalence (90.32%) of confirmed *E. coli* isolates. Antimicrobial susceptibility testing showed widespread multidrug resistance (MDR), with the highest resistance to ampicillin and tetracycline. The *mcr-1* gene was the most common colistin resistance gene, detected in over 50% of isolates. Whole-genome sequencing of selected isolates revealed diverse sequence types, virulence factors, and AMR genes, including *mcr-1.1*. Plasmid analysis indicated a high potential for horizontal gene transfer, particularly in isolates carrying IncF, IncHI2, and IncX1 plasmids. These results highlight a significant public health concern regarding the spread of MDR and colistin-resistant *E. coli* in the swine industry.

Author Contributions: Conceptualization, R.W., P.T., D.H.P., S.B., and R.B.; Methodology, R.W., N.S., C.P., Y.K., N.P., H.K., S.T., S.B., and R.B.; Investigation, R.W., Y.K., N.P., S.B., and R.B.; Data curation, R.W., P.T., N.S., C.P., S.B., and R.B.; Resources, R.W., P.T., and R.B.; Writing—original draft, R.W., P.T., N.S., S.T., and R.B.; Writing—review and editing, R.W., P.T., N.S., C.P., D.H.P., S.B., H.K., S.T., and R.B.; Conceptualization, R.B.; Formal analysis, R.W. and R.B. Data curation, R.B.; Resources, R.B.; Supervision, R.B.; Project administration, R.B.; Funding acquisition, R.B. All authors have read and agreed to the published version of the manuscript.

Funding: This work was partially supported by Walailak University under the new researcher development scheme (Grant Number WU69215) and the international research collaboration scheme (Grant Number: WU-CIA-06507/2025).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the article.

Acknowledgments: We would like to thank the One Health Research Center, Walailak University, Thailand, for their support. We thank Walailak University for supporting this research under the New Researcher Development Scheme (Grant Number WU69215) and the International Research Collaboration Scheme (Grant Number WU-CIA-06507/2025).

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Alhadlaq, M.A.; Aljurayyad, O.I.; Almansour, A.; Al-Akeel, S.I.; Alzahrani, K.O.; Alsalman, S.A.; Yahya, R.; Al-Hindi, R.R.; Hakami, M.A.; Alshahrani, S.D.; et al. Overview of pathogenic *Escherichia coli*, with a focus on Shiga toxin-producing serotypes, global outbreaks (1982–2024) and food safety criteria. *Gut Pathog.* **2024**, *16*, 57. [\[CrossRef\]](#)
2. Denamur, E.; Clermont, O.; Bonacorsi, S.; Gordon, D. The population genetics of pathogenic *Escherichia coli*. *Nat. Rev. Microbiol.* **2021**, *19*, 37–54. [\[CrossRef\]](#)
3. Duc, H.M.; Ha, C.T.T.; Hoa, T.T.K.; Hung, L.V.; Thang, N.V.; Son, H.M. Prevalence, molecular characterization, and antimicrobial resistance profiles of Shiga toxin-producing *Escherichia coli* isolated from raw beef, pork, and chicken meat in Vietnam. *Foods* **2024**, *13*, 2059. [\[CrossRef\]](#)
4. Lay, K.K.; Jeamsripong, S.; Sunn, K.P.; Angkititrakul, S.; Prathan, R.; Srisanga, S.; Chuanchuen, R. Colistin resistance and ESBL production in *Salmonella* and *Escherichia coli* from pigs and pork in the Thailand, Cambodia, Lao PDR, and Myanmar border area. *Antibiotics* **2021**, *10*, 657. [\[CrossRef\]](#)
5. Srichumporn, W.; Chaisowwong, W.; Intanon, M.; Na-Lampang, K. Extended-spectrum beta-lactamase-producing *Escherichia coli* from pork in Muang district, Chiang Mai Province, Thailand. *Vet. World* **2022**, *15*, 2903–2909. [\[CrossRef\]](#)
6. Klaharn, K.; Pichpol, D.; Meeyam, T.; Harintharanon, T.; Loha-anukul, P.; Punyapornwithaya, V. Bacterial contamination of chicken meat in slaughterhouses and the associated risk factors: A nationwide study in Thailand. *PLoS ONE* **2022**, *17*, e0269416. [\[CrossRef\]](#)
7. Wang, L.; Liu, N.; Gao, Y.; Liu, J.; Huang, X.; Zhang, Q.; Li, Y.; Zhao, J.; Wang, J.; Zhao, G. Surveillance and reduction control of *Escherichia coli* and diarrheagenic *E. coli* during the pig slaughtering process in China. *Front. Vet. Sci.* **2021**, *8*, 735076. [\[CrossRef\]](#) [\[PubMed\]](#)
8. Geurtsen, J.; de Been, M.; Weerdenburg, E.; Zomer, A.; McNally, A.; Poolman, J. Genomics and pathotypes of the many faces of *Escherichia coli*. *FEMS Microbiol. Rev.* **2022**, *46*, fuac031. [\[CrossRef\]](#)
9. Nardulli, P.; Ballini, A.; Zamparella, M.; De Vito, D. The role of stakeholders' understandings in emerging antimicrobial resistance: A One Health approach. *Microorganisms* **2023**, *11*, 2797. [\[CrossRef\]](#) [\[PubMed\]](#)
10. Sharma, J.; Sharma, D.; Singh, A.; Sunita, K. Colistin resistance and management of drug-resistant infections. *Can. J. Infect. Dis. Med. Microbiol.* **2022**, *2022*, 4315030. [\[CrossRef\]](#) [\[PubMed\]](#)
11. Pungpian, C.; Lee, S.; Trongjit, S.; Sinwat, N.; Angkititrakul, S.; Prathan, R.; Srisanga, S.; Chuanchuen, R. Colistin resistance and plasmid-mediated *mcr* genes in *Escherichia coli* and *Salmonella* isolated from pigs, pig carcass and pork in Thailand, Lao PDR and Cambodia border provinces. *J. Vet. Sci.* **2021**, *22*, e68. [\[CrossRef\]](#)
12. Peng, Z.; Zhang, X.; Li, X.; Hu, Z.; Li, Z.; Jia, C.; Dai, M.; Tan, C.; Chen, H.; Wang, X. Characteristics of colistin-resistant *Escherichia coli* from pig farms in Central China. *Anim. Dis.* **2021**, *1*, 9. [\[CrossRef\]](#)

13. Khine, N.O.; Lugsomya, K.; Niyomtham, W.; Pongpan, T.; Hampson, D.J.; Prapasarakul, N. Longitudinal monitoring reveals persistence of colistin-resistant *Escherichia coli* on a pig farm following cessation of colistin use. *Front. Vet. Sci.* **2022**, *9*, 845746. [CrossRef]
14. Rega, M.; Carmosino, I.; Bonilauri, P.; Frascolla, V.; Vismarra, A.; Bacci, C. Prevalence of ESBL, AmpC and colistin-resistant *E. coli* in meat: A comparison between pork and wild boar. *Microorganisms* **2021**, *9*, 214. [CrossRef]
15. Dang, S.T.T.; Truong, D.T.Q.; Olsen, J.E.; Tran, N.T.; Truong, G.T.H.; Vu, H.T.K.; Dalsgaard, A. Occurrence of *mcr*-encoded colistin resistance in *Escherichia coli* from pigs and pig farm workers in Vietnam. *FEMS Microbes* **2020**, *1*, xtaa003. [CrossRef]
16. Mondal, A.H.; Khare, K.; Saxena, P.; Debnath, P.; Mukhopadhyay, K.; Yadav, D. A review on colistin resistance: An antibiotic of last resort. *Microorganisms* **2024**, *12*, 772. [CrossRef]
17. Moberg, G.P.; Mench, J.A. *The Biology of Animal Stress: Basic Principles and Implications for Animal Welfare*; CABI Publishing: Wallingford, UK, 2000.
18. Verbrugghe, E.; Boyen, F.; Van Parys, A.; Van Deun, K.; Croubels, S.; Thompson, A.; Shearer, N.; Leyman, B.; Haesebrouck, F.; Pasmans, F. Stress-induced *Salmonella* Typhimurium recrudescence in pigs coincides with cortisol-induced increased intracellular proliferation in macrophages. *Vet. Res.* **2011**, *42*, 118. [CrossRef]
19. Bailey, M.T.; Dowd, S.E.; Galley, J.D.; Hufnagle, A.R.; Allen, R.G.; Lyte, M. Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation. *Brain Behav. Immun.* **2011**, *25*, 397–407. [CrossRef]
20. Line, J.E.; Bailey, J.S.; Cox, N.A.; Stern, N.J.; Tompkins, T. Effect of yeast-supplemented feed on *Salmonella* and *Campylobacter* populations in broilers. *Poultry Sci.* **1998**, *77*, 405–410. [CrossRef]
21. Phodha, T.; Riewpaiboon, A.; Malathum, K.; Coyte, P.C. Annual relative increase in inpatient mortality from antimicrobial resistant nosocomial infections in Thailand. *Epidemiol. Infect.* **2019**, *147*, e133. [CrossRef]
22. Phodha, T.; Riewpaiboon, A.; Malathum, K.; Coyte, P.C. Excess annual economic burdens from nosocomial infections caused by multi-drug-resistant bacteria in Thailand. *Expert Rev. Pharmacoecon. Outcomes Res.* **2019**, *19*, 305–312. [CrossRef]
23. Sudatip, D.; Tiengrim, S.; Chasiri, K.; Kritiyakan, A.; Phanprasit, W.; Morand, S.; Thamlikitkul, V. One Health surveillance of antimicrobial resistance phenotypes in selected communities in Thailand. *Antibiotics* **2022**, *11*, 556. [CrossRef]
24. World Health Organization (WHO). Antimicrobial Resistance: Fact Sheet. Available online: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance> (accessed on 9 October 2024).
25. Salam, M.A.; Al-Amin, M.Y.; Salam, M.T.; Pawar, J.S.; Akhter, N.; Rabaan, A.A.; Alqumber, M.A.A. Antimicrobial resistance: A growing serious threat for global public health. *Healthcare* **2023**, *11*, 1946. [CrossRef]
26. Smit, C.C.H.; Lambert, M.; Rogers, K.; Djordjevic, S.P.; Van Oijen, A.M.; Keighley, C.; Taxis, K.; Robertson, H.; Pont, L.G. One Health determinants of *Escherichia coli* antimicrobial resistance in humans in the community: An umbrella review. *Int. J. Mol. Sci.* **2023**, *24*, 17204. [CrossRef]
27. Olaitan, A.O.; Morand, S.; Rolain, J.-M. Mechanisms of polymyxin resistance: Acquired and intrinsic resistance in bacteria. *Front. Microbiol.* **2014**, *5*, 643. [CrossRef]
28. Valiakos, G.; Kapna, I. Colistin Resistant *mcr* Genes Prevalence in Livestock Animals (Swine, Bovine, Poultry) from a Multinational Perspective. A Systematic Review. *Vet. Sci.* **2021**, *8*, 265. [CrossRef]
29. Nguyen, N.T.; Nguyen, H.M.; Nguyen, C.V.; Nguyen, T.V.; Nguyen, M.T.; Thai, H.Q.; Ho, M.H.; Thwaites, G.; Ngo, H.T.B.; Baker, S.; et al. Use of Colistin and Other Critical Antimicrobials on Pig and Chicken Farms in Southern Vietnam and Its Association with Resistance in Commensal *Escherichia coli* Bacteria. *Appl. Environ. Microbiol.* **2016**, *82*, e00337-16. [CrossRef]
30. Elbediwi, M.; Li, Y.; Paudyal, N.; Pan, H.; Li, X.; Xie, S.; Rajkovic, A.; Feng, Y.; Fang, W.; Rankin, S.C.; et al. Global burden of colistin-resistant bacteria: Mobilized colistin resistance genes study (1980–2018). *Microorganisms* **2019**, *7*, 461. [CrossRef]
31. Dadashi, M.; Sameni, F.; Bostanshirin, N.; Yaslianifard, S.; Khosravi-Dehaghi, N.; Nasiri, M.J.; Goudarzi, M.; Hashemi, A.; Hajikhani, B. Global prevalence and molecular epidemiology of *mcr*-mediated colistin resistance in *Escherichia coli* clinical isolates: A systematic review. *J. Glob. Antimicrob. Resist.* **2022**, *29*, 444–461. [CrossRef]
32. Yin, W.; Li, H.; Shen, Y.; Liu, Z.; Wang, S.; Shen, Z.; Zhang, R.; Walsh, T.R.; Shen, J.; Wang, Y. Novel plasmid-mediated colistin resistance gene *mcr-3* in *Escherichia coli*. *mBio* **2017**, *8*, e00543-17. [CrossRef]
33. Bastidas-Caldes, C.; de Waard, J.H.; Salgado, M.S.; Villacis, M.J.; Coral-Almeida, M.; Yamamoto, Y.; Calvopiña, M. Worldwide prevalence of *mcr*-mediated colistin-resistant *Escherichia coli* in isolates of clinical samples, healthy humans, and livestock—A systematic review and meta-analysis. *Pathogens* **2022**, *11*, 659. [CrossRef]
34. Khanawapee, A.; Kerdsin, A.; Chopjitt, P.; Boueroy, P.; Hatrongjit, R.; Akeda, Y.; Tomono, K.; Nuanualsuwan, S.; Hamada, S. Distribution and molecular characterization of *Escherichia coli* harboring *mcr* genes isolated from slaughtered pigs in Thailand. *Microb. Drug Resist.* **2021**, *27*, 971–979. [CrossRef]
35. Cheng, P.; Yang, Y.; Cao, S.; Liu, H.; Li, X.; Sun, J.; Li, F.; Ishfaq, M.; Zhang, X. Prevalence and characteristic of swine-origin *mcr-1*-positive *Escherichia coli* in Northeastern China. *Front. Microbiol.* **2021**, *12*, 712707. [CrossRef]

36. Viñes, J.; Cuscó, A.; Napp, S.; Alvarez, J.; Saez-Llorente, J.L.; Rosàs-Rodoreda, M.; Francino, O.; Migura-Garcia, L. Transmission of similar Mcr-1 carrying plasmids among different *Escherichia coli* lineages isolated from livestock and the farmer. *Antibiotics* **2021**, *10*, 313. [\[CrossRef\]](#) [\[PubMed\]](#)
37. Ekhlas, D.; Argüello, H.; Leonard, F.C.; Manzanilla, E.G.; Burgess, C.M. Insights on the effects of antimicrobial and heavy metal usage on the antimicrobial resistance profiles of pigs based on culture-independent studies. *Vet. Res.* **2023**, *54*, 14. [\[CrossRef\]](#)
38. Amaro, A.; Leão, C.; Guerra, V.; Albuquerque, T.; Clemente, L. Plasmid-mediated colistin resistance genes *mcr-1* and *mcr-4* in multidrug-resistant *Escherichia coli* strains isolated from a healthy pig in Portugal. *Microb. Drug Resist.* **2023**, *29*, 78–84. [\[CrossRef\]](#)
39. García, V.; García-Meniño, I.; Mora, A.; Flament-Simon, S.C.; Díaz-Jiménez, D.; Blanco, J.E.; Alonso, M.P.; Blanco, J. Co-occurrence of *mcr-1*, *mcr-4* and *mcr-5* genes in multidrug-resistant ST10 enterotoxigenic and Shiga toxin-producing *Escherichia coli* in Spain (2006–2017). *Int. J. Antimicrob. Agents* **2018**, *52*, 104–108. [\[CrossRef\]](#)
40. Luo, Q.; Wang, Y.; Xiao, Y. Prevalence and transmission of mobilized colistin resistance (*mcr*) gene in bacteria common to animals and humans. *Biosaf. Health* **2020**, *2*, 71–78. [\[CrossRef\]](#)
41. Kaushik, P.; Anjay, A.; Kumari, S.; Dayal, S.; Kumar, S. Antimicrobial resistance and molecular characterisation of *Escherichia coli* from poultry in Eastern India. *Vet. Ital.* **2019**, *54*, 197–204. [\[CrossRef\]](#)
42. Madec, J.-Y.; Haenni, M.; Nordmann, P.; Poirel, L. Extended-spectrum β -lactamase/AmpC- and carbapenemase-producing *Enterobacteriaceae* in animals: A threat for humans? *Clin. Microbiol. Infect.* **2017**, *23*, 826–833. [\[CrossRef\]](#)
43. Liu, Z.; Wang, S.; Gao, T.; Liu, W.; Yuan, F.; Wu, Q.; Chang, L.; Guo, R.; Tan, Y. Prevalence, molecular characterization, and antimicrobial resistance profile of enterotoxigenic *Escherichia coli* isolates from pig farms in China. *Foods* **2025**, *14*, 1188. [\[CrossRef\]](#) [\[PubMed\]](#)
44. Trongjit, S.; Angkittitrakul, S.; Chuanchuen, R. Occurrence and molecular characteristics of antimicrobial resistance of *Escherichia coli* from broilers, pigs and meat products in Thailand and Cambodia provinces. *Microbiol. Immunol.* **2016**, *60*, 575–585. [\[CrossRef\]](#)
45. Mitsuwana, W.; Intongead, S.; Saengsawang, P.; Romyasamit, C.; Narinthorn, R.; Nissapatorn, V.; Pereira, M.L.; Paul, A.K.; Wongtawan, T.; Boripun, R. Occurrence of multidrug resistance associated with extended-spectrum β -lactamase and the biofilm-forming ability of *Escherichia coli* in environmental swine husbandry. *Comp. Immunol. Microbiol. Infect. Dis.* **2023**, *103*, 102093. [\[CrossRef\]](#)
46. Van Boeckel, T.P.; Brower, C.; Gilbert, M.; Grenfell, B.T.; Levin, S.A.; Robinson, T.P.; Teillant, A.; Laxminarayan, R. Global trends in antimicrobial use in food animals. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 5649–5654. [\[CrossRef\]](#)
47. Liu, H.; Wang, L.; Peng, Q.; Li, Y.; Zhou, H. Molecular characterization of extended-spectrum β -lactamase-producing multidrug resistant *Escherichia coli* from swine in Northwest China. *Front. Microbiol.* **2018**, *9*, 1756. [\[CrossRef\]](#)
48. Ma, J.; Zhou, W.; Wu, J.; Liu, X.; Lin, J.; Ji, X.; Lin, H.; Wang, J.; Jiang, H.; Zhou, Q.; et al. Large-Scale Studies on Antimicrobial Resistance and Molecular Characterization of *Escherichia coli* from Food Animals in Developed Areas of Eastern China. *Microbiol. Spectr.* **2022**, *10*, e02015-22. [\[CrossRef\]](#)
49. Todorović, D.; Velhner, M.; Grego, E.; Vidanović, D.; Milanov, D.; Krnjaić, D.; Kehrenberg, C. Molecular Characterization of Multidrug-Resistant *Escherichia coli* Isolates from Bovine Clinical Mastitis and Pigs in the Vojvodina Province, Serbia. *Microb. Drug Resist.* **2018**, *24*, 95–103. [\[CrossRef\]](#)
50. Van, T.H.; Chin, J.; Chapman, T.; Tran, L.T.; Coloe, P.J. Safety of raw meat and shellfish in Vietnam: An analysis of *Escherichia coli* isolations for antibiotic resistance and virulence genes. *Int. J. Food Microbiol.* **2008**, *124*, 217–223. [\[CrossRef\]](#)
51. Falgenhauer, L.; Imirzalioglu, C.; Oppong, K.; Wiafe Akenten, C.; Hogan, B.; Krumkamp, R.; Poppert, S.; Levermann, V.; Schwengers, O.; Sarpong, N.; et al. Detection and Characterization of ESBL-Producing *Escherichia coli* from Humans and Poultry in Ghana. *Front. Microbiol.* **2018**, *9*, 3358. [\[CrossRef\]](#) [\[PubMed\]](#)
52. Intongead, S.; Saengsawang, P.; Boonmar, S.; Morita, Y.; Mitsuwana, W.; Narinthorn, R.; Boripun, R. Extended-spectrum β -lactamase-producing *Escherichia coli* in retail pork and market environments: Genetic diversity and antimicrobial resistance in Thailand. *Foodborne Pathog. Dis.* **2025**, in press. [\[CrossRef\]](#) [\[PubMed\]](#)
53. Ewers, C.; Grobbel, M.; Stamm, I.; Kopp, P.A.; Diehl, I.; Semmler, T.; Fruth, A.; Beutlich, J.; Guerra, B.; Wieler, L.H.; et al. Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum- β -lactamase-producing *Escherichia coli* among companion animals. *J. Antimicrob. Chemother.* **2010**, *65*, 651–660. [\[CrossRef\]](#)
54. Tamayo-Legorreta, E.M.; García-Radilla, A.; Moreno-Vázquez, E.; Téllez-Figueroa, F.; Alpuche-Aranda, C.M. Diarrheagenic *Escherichia coli* pathotypes isolated from a swine farm in a region of Morelos state, Mexico. *Salud Publica Mex.* **2020**, *63*, 34–41. [\[CrossRef\]](#)
55. Kagambèga, A.; Martikainen, O.; Siitonen, A.; Traoré, A.S.; Barro, N.; Haukka, K. Prevalence of diarrheagenic *Escherichia coli* virulence genes in the feces of slaughtered cattle, chickens, and pigs in Burkina Faso. *MicrobiologyOpen* **2012**, *1*, 276–284. [\[CrossRef\]](#)
56. Santos, A.C.M.; Silva, R.S.; Vieira, M.A.M.; Niero, C.V.; Ribeiro, M.S.F.; Guth, B.E.C.; Gomes, T.A.T.; Silva, R.M. The diverse virulence potential of atypical enteropathogenic *Escherichia coli* isolated from diarrhea: The emergence of a hybrid pathotype? *Front. Microbiol.* **2025**, *16*, 1599350. [\[CrossRef\]](#)

57. Vilaró, A.; Serra, L.; Solé, E.; Seró, I.; Novell, E.; Enrique-Tarancón, V.; Fraile, L.; Migura-Garcia, L. Exploring the epidemiology and genetic complexity of *Escherichia coli* in vertically integrated pig production systems using whole genome sequencing. *Vet. Microbiol.* **2025**, *307*, 110610. [\[CrossRef\]](#)
58. Do, K.-H.; Byun, J.-W.; Lee, W.-K. Virulence genes and antimicrobial resistance of pathogenic *Escherichia coli* isolated from diarrheic weaned piglets in Korea. *J. Anim. Sci. Technol.* **2020**, *62*, 543–552. [\[CrossRef\]](#) [\[PubMed\]](#)
59. Essendoubi, S.; Yang, X.; King, R.; Keenlside, J.; Bahamon, J.; Diegel, J.; Lu, P.; Cassis, R.; Gensler, G.; Stashko, N.; et al. Prevalence and characterization of *Escherichia coli* O157:H7 on pork carcasses and in swine colon contents from provincially licensed abattoirs in Alberta, Canada. *J. Food Prot.* **2020**, *83*, 1909–1917. [\[CrossRef\]](#) [\[PubMed\]](#)
60. Göpel, L.; Prenger-Berninghoff, E.; Wolf, S.A.; Semmler, T.; Bauerfeind, R.; Ewers, C. Occurrence of mobile colistin resistance genes *mcr-1*–*mcr-10* including novel *mcr* gene variants in different pathotypes of porcine *Escherichia coli* isolates collected in Germany from 2000 to 2021. *Appl. Microbiol.* **2024**, *4*, 70–84. [\[CrossRef\]](#)
61. Coelho, M.M.S.; Davanzo, E.F.A.; dos Santos, R.L.; Castro, V.H.L.; da Costa, H.M.B.; Dallago, B.S.L.; Perecmanis, S.; Santana, A.P. *Escherichia coli* and Enterobacteriaceae counts, virulence gene profile, antimicrobial resistance, and biofilm formation capacity during pig slaughter stages. *Life* **2024**, *14*, 1261. [\[CrossRef\]](#)
62. Shao, J.; Dai, H.; Xu, L.; Zhu, S.; Zhu, J.; Fu, H.; Ge, M.; He, X. Genomic characteristics of extended spectrum β -lactamase producing *Escherichia coli* isolates recovered from a district hospital in China. *Infect. Drug Resist.* **2023**, *16*, 3589–3600. [\[CrossRef\]](#)
63. Touchon, M.; Hoede, C.; Tenaillon, O.; Barbe, V.; Baeriswyl, S.; Bidet, P.; Bingen, E.; Bonacorsi, S.; Bouchier, C.; Bouvet, O.; et al. Organised genome dynamics in the *Escherichia coli* species results in highly diverse adaptive paths. *PLoS Genet.* **2009**, *5*, e1000344. [\[CrossRef\]](#)
64. Chen, Z.; Kuang, D.; Xu, X.; González-Escalona, N.; Erickson, D.L.; Brown, E.; Meng, J. Genomic analyses of multidrug-resistant *Salmonella* Indiana, Typhimurium, and Enteritidis isolates using MinION and MiSeq sequencing technologies. *PLoS ONE* **2020**, *15*, e0235641. [\[CrossRef\]](#)
65. Joensen, K.G.; Scheut, F.; Lund, O.; Hasman, H.; Kaas, R.S.; Nielsen, E.M.; Aarestrup, F.M. Real-time whole-genome sequencing for routine typing, surveillance, and outbreak detection of verotoxigenic *Escherichia coli*. *J. Clin. Microbiol.* **2014**, *52*, 1501–1510. [\[CrossRef\]](#)
66. Mathers, A.J.; Cox, H.L.; Kitchel, B.; Bonatti, H.; Brassinga, A.K.; Carroll, J.; Scheld, W.M.; Hazen, K.C.; Sifri, C.D. Molecular dissection of an outbreak of carbapenem-resistant Enterobacteriaceae reveals intergenus KPC carbapenemase transmission through a promiscuous plasmid. *mBio* **2011**, *2*, e00204-11. [\[CrossRef\]](#)
67. Manges, A.R.; Geum, H.M.; Guo, A.; Edens, T.J.; Fibke, C.D.; Pitout, J.D.D. Global extraintestinal pathogenic *Escherichia coli* (ExPEC) lineages. *Clin. Microbiol. Rev.* **2019**, *32*, e00135-18. [\[CrossRef\]](#) [\[PubMed\]](#)
68. Nguyen, Y.; Sperandio, V. Enterohemorrhagic *E. coli* (EHEC) pathogenesis. *Front. Cell. Infect. Microbiol.* **2012**, *2*, 90. [\[CrossRef\]](#)
69. Pokharel, P.; Dhakal, S.; Dozois, C.M. The diversity of *Escherichia coli* pathotypes and vaccination strategies against this versatile bacterial pathogen. *Microorganisms* **2023**, *11*, 344. [\[CrossRef\]](#)
70. Stoesser, N.; Batty, E.M.; Eyre, D.W.; Morgan, M.; Wyllie, D.H.; Del Ojo Elias, C.; Johnson, J.R.; Walker, A.S.; Peto, T.E.; Crook, D.W. Predicting antimicrobial susceptibilities for *Escherichia coli* and *Klebsiella pneumoniae* isolates using whole genomic sequence data. *J. Antimicrob. Chemother.* **2013**, *68*, 2234–2244. [\[CrossRef\]](#) [\[PubMed\]](#)
71. Carattoli, A. Resistance plasmid families in Enterobacteriaceae. *Antimicrob. Agents Chemother.* **2009**, *53*, 2227–2238. [\[CrossRef\]](#) [\[PubMed\]](#)
72. Wang, Z.; Fu, Y.; Schwarz, S.; Yin, W.; Walsh, T.R.; Zhou, Y.; He, J.; Jiang, H.; Wang, Y.; Wang, S. Genetic environment of colistin resistance genes *mcr-1* and *mcr-3* in *Escherichia coli* from one pig farm in China. *Vet. Microbiol.* **2019**, *230*, 56–61. [\[CrossRef\]](#)
73. Tyson, G.H.; Li, C.; Hsu, C.-H.; Ayers, S.; Borenstein, S.; Mukherjee, S.; Tran, T.T.; McDermott, P.F.; Zhao, S. The *mcr-9* gene of *Salmonella* and *Escherichia coli* is not associated with colistin resistance in the United States. *Antimicrob. Agents Chemother.* **2020**, *64*, e00573-20. [\[CrossRef\]](#) [\[PubMed\]](#)
74. Babu, L.; Reddy, P.; Murali, H.S.; Batra, H.V. Optimization and evaluation of a multiplex PCR for simultaneous detection of prominent foodborne pathogens of Enterobacteriaceae. *Ann. Microbiol.* **2013**, *63*, 1591–1599. [\[CrossRef\]](#)
75. Rebelo, A.R.; Bortolaia, V.; Kjeldgaard, J.S.; Pedersen, S.K.; Leekitcharoenphon, P.; Hansen, I.M.; Guerra, B.; Malorny, B.; Borowiak, M.; Hammerl, J.A.; et al. Multiplex PCR for detection of plasmid-mediated colistin resistance determinants, *mcr-1*, *mcr-2*, *mcr-3*, *mcr-4* and *mcr-5* for surveillance purposes. *Euro Surveill.* **2018**, *23*, 1700672. [\[CrossRef\]](#)
76. Liu, J.; Zhang, Z.; Feng, Y.; Hu, H.; Yu, Y.; Qiu, L.; Liu, H.; Guo, Z.; Huang, J.; Du, C.; et al. Molecular detection of the *mcr* genes by multiplex PCR. *Infect. Drug Resist.* **2020**, *13*, 3463–3468. [\[CrossRef\]](#)
77. Azimi, T.; Azimi, L.; Fallah, F.; Pourmand, M.R.; Ostadtaghizadeh, A.; Abai, M.R.; Rahimi Foroushani, A. Detection and characterization of Enterobacteriaceae family members carried by commensal *Rattus norvegicus* from Tehran, Iran. *Arch. Microbiol.* **2021**, *203*, 1321–1334. [\[CrossRef\]](#)

78. Seenama, C.; Thamlikitkul, V.; Ratthawongjirakul, P. Multilocus sequence typing and *bla*ESBL characterization of extended-spectrum beta-lactamase producing *Escherichia coli* isolated from healthy humans and swine in Northern Thailand. *Infect. Drug Resist.* **2019**, *12*, 2201–2214. [[CrossRef](#)] [[PubMed](#)]
79. Rajivgandhi, G.; Maruthupandy, M.; Ramachandran, G.; Priyanga, M.; Manoharan, N. Detection of ESBL genes from ciprofloxacin resistant Gram-negative bacteria isolated from urinary tract infections (UTIs). *Front. Lab. Med.* **2018**, *2*, 5–13. [[CrossRef](#)]
80. Lungu, B.C.; Hutu, I.; Barrow, P.A. Molecular characterisation of antimicrobial resistance in *E. coli* isolates from piglets in the West Region of Romania. *Antibiotics* **2023**, *12*, 1544. [[CrossRef](#)]
81. CLSI Guidelines (2019) CLSI M100-ED29: 2019 Performance Standards for Antimicrobial Susceptibility Testing, 29th ed.; Clinical & Laboratory Standards Institute: Wayne, PA, USA, 2019.
82. Bortolaia, V.; Kaas, R.S.; Ruppe, E.; Roberts, M.C.; Schwarz, S.; Cattoir, V.; Philippon, A.; Allesoe, R.L.; Rebelo, A.R.; Florensa, A.F.; et al. ResFinder 4.0 for predictions of phenotypes from genotypes. *J. Antimicrob. Chemother.* **2020**, *75*, 3491–3500. [[CrossRef](#)]
83. Johansson, M.H.K.; Bortolaia, V.; Tansirichaiya, S.; Aarestrup, F.M.; Roberts, A.P.; Petersen, T.N. Detection of mobile genetic elements associated with antibiotic resistance in *Salmonella enterica* using a newly developed web tool: MobileElementFinder. *J. Antimicrob. Chemother.* **2021**, *76*, 101–109. [[CrossRef](#)] [[PubMed](#)]
84. Liu, B.; Zheng, D.; Zhou, S.; Chen, L.; Yang, J. VFDB 2022: A general classification scheme for bacterial virulence factors. *Nucleic Acids Res.* **2022**, *50*, D912–D917. [[CrossRef](#)] [[PubMed](#)]
85. R Core Team. *R: A Language and Environment for Statistical Computing*; R Foundation for Statistical Computing: Vienna, Austria, 2025. Available online: <https://www.r-project.org/> (accessed on 1 December 2025).

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.